Periscope Capital’s ZyVersa Therapeutics ZVSA Stock Holding History

Periscope Capital’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-835	Closed	-$2.92M	–	945
2022 Q3	$2.92M	Hold	835	–	–	0.08%	431
2022 Q2	$2.9M	Buy	835 +802	+2,430%	+$2.79M	0.08%	486
2022 Q1	$115K	Buy	+33	New	+$114K	﹤0.01%	737

Other funds holding ZVSA

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

Periscope Capital's ZVSA Position: Q4 2022 in Review

Periscope Capital sold out of ZyVersa Therapeutics (ZVSA) in Q4 2022, closing a stake of 835 shares — an estimated $2.92M sold.

Periscope Capital first reported a position in ZVSA in Q1 2022 and held it in 3 quarters. The position peaked at $2.92M in Q3 2022. 2 funds tracked by Wall St. Rank hold ZVSA as of Q4 2022.

Periscope Capital reported no remaining ZyVersa Therapeutics position as of Q4 2022 after selling out during the quarter.
Periscope Capital sold 835 ZyVersa Therapeutics shares in Q4 2022, an estimated $2.92M.
Periscope Capital first reported a position in ZyVersa Therapeutics in Q1 2022 and held it in 3 quarters.
Periscope Capital's ZyVersa Therapeutics position peaked at $2.92M in Q3 2022.
2 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q4 2022.

Based on Periscope Capital's 13F filing for Q4 2022, filed 13 Feb 2023.